Reporter brief
RCT of oral everolimus alone or with lucentis for neovascular age-related macular degeneration; results not reported
What happened
A randomised, double-masked, parallel group study designed to assess the safety and efficacy of oral everolimus (an mTOR inhibitor in the rapamycin class) alone or combined with lucentis in patients with neovascular age-related macular degeneration. No efficacy or safety results were reported in the material provided.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Patients with neovascular age-related macular degeneration (AMD)
- Design
- Rct
- Sample
- —
- Journal
- Novartis Pharmaceuticals
- Published
- Aug 19, 2011
Effect size
Not recorded.
Caveats
- Assessment: Pending.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Novartis Pharmaceuticals (sponsor) · Study sponsored by Novartis Pharmaceuticals, manufacturer of both Everolimus (RAD001) and Lucentis
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.